The trial was RucaPANC for maintenance monotherapy and targeted BRCA1, BRCA2, PALB2 mutations using the PARP-1 inhibitor Rucaparib (Rubraca).

More details on the trial-

PARP STUDY AT PennMedicine
https://ascopubs.org/doi/10.1200/PO.17.00316
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6057747/
This is a YouTube video of my case by pancreatic cancer oncologist Dr. Kim Reiss-Binder at PennMedicine. It starts at time stamp 1:00 and the conclusion is at the end of the presentation.